Moderna’s Stock Soars On Positive Early-stage Data For Its Coronavirus Vaccine Candidate


The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.

Editor’s note: This is not investment advice by us. Just a health news and optimism.

Source: Market Watch

Shares of Moderna Inc. (MRNA) jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said.

There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. “These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25” micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna’s vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus.

The preclinical company said earlier this month that the Phase 2 trial will begin “shortly,” and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna’s stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.


The best of the Muslim Times’ collection for war against Covid 19:

In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.

There are believers in the discovery reported today and then there are the critics:

Prime Minister Shinzo Abe says more than 30 countries have asked Japan for favipiravir (Avigan) to fight Covid 19

For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology

Kaiser Permanente launches first coronavirus vaccine trial

Corona Fear’s Cure: Chanting from the Bible and the Quran

Can You Chant from the Bible or the Quran to Bliss and Happiness?

Japanese flu drug ‘clearly effective’ in treating coronavirus, says China

Synthetic antibodies might offer a quick coronavirus treatment

The Four Possible Timelines for Life Returning to Normal

The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic

Coronavirus: TB Vaccination Trial Started in Melbourne, Australia

The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources

All of humanity are intimate neighbors: Coronavirus proves it once again

Praise be to God for the Miracle of Our Immune System

USA: 15-minute coronavirus test is here

Does the Ordinary Soap Kill Coronavirus?

Here’s a list of disinfectants you can use against coronavirus

For the number of cases and epidemiology in each country go to: WorldOMeters

Categories: The Muslim Times, Vaccine

1 reply

  1. Moderna, the Massachusetts biotechnology company behind a leading effort to create a coronavirus vaccine, announced promising early results from its first human safety tests Monday. The company plans to launch a large clinical trial in July aimed at showing whether the vaccine works.

    The company reported that in eight patients who had been followed for a month and a half, the vaccine at low and medium doses triggered blood levels of virus-fighting antibodies that were similar or greater than those found in patients who recovered. That would suggest, but doesn’t prove, that it triggers some level of immunity. The antibody-rich blood plasma donated by patients who have recovered is separately being tested to determine whether it is an effective therapy or preventive measure for covid-19.

    Moderna’s announcement comes days after one of its directors, Moncef Slaoui, stepped down from the board to become chief scientist for Operation Warp Speed, a White House initiative to speed up vaccine development. Watchdogs called out Slaoui’s apparent conflict of interest, noting he owns stock options worth $10 million in Moderna, and made an apparent reference to the early data in a Rose Garden news conference on Friday afternoon.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.